

LABORATORY CORP OF AMERICA HOLDINGS  
Form 8-K  
July 21, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 21, 2005

(Date of earliest event reported)

**LABORATORY CORPORATION OF  
AMERICA HOLDINGS**

---

(Exact Name of Registrant as Specified in its Charter)

**DELAWARE**

**1-11353**

**13-3757370**

---

(State or other jurisdiction  
of Incorporation)

(Commission  
File Number)

(I.R.S.  
Employer  
Identification  
No.)

**358 SOUTH MAIN STREET,  
BURLINGTON, NORTH CAROLINA**

**27215**

**336-229-1127**

---

(Address of principal executive offices)

(Zip  
Code)

(Registrant's telephone number including area  
code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company dated July 21, 2005.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings  
(Registrant)

Date: July 21, 2005

By: /s/Bradford T. Smith  
Bradford T. Smith, Executive Vice  
President  
and Secretary

8-K Filed July 21, 2005

*This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2004, and subsequent filings.*

2

**The Clinical Laboratory Testing  
Market - \$40 billion Annually**

Independent clinical lab share  
is \$16 billion

Represents 2% to 3% of all  
health care spending

Influences /directs  
approximately 80% of health  
care spending

Rapidly evolving technology,  
emphasis on preventative  
medicine and aging of  
population are all driving  
growth

Has grown at a CAGR of  
between 5% and 6%

**Source: Company estimates, industry reports and 2004 revenue for LabCorp.**

3

**Profile of LabCorp**

A leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America

Offers a broad range of routine and esoteric/genomic tests

Conducts testing on more than 360,000 specimens daily

Provides lab services to physicians and other health care providers

Approximately 25,000 employees nationwide

4

**Primary Testing Locations & PSCs**

Primary LabCorp Testing Locations

Patient Service Centers

**PR**

**AK**

Corporate Headquarters

Burlington, NC

5

**LabCorp's Investment and  
Performance Fundamentals**

History of Strong Financial  
Performance

Significant Cash Generator

Industry leading EBITDA margins

Strong Balance Sheet

Investment Grade Credit Ratings

6

**Net Sales (in millions)**

7



**EBITDA Margin**

8

**EPS**

9

**Operating Cash Flow (in millions)**

*(1) Includes approximately \$50 million of benefit from one-time tax credits recorded in 2003.*

*(1)*

10

To **lead** the industry in achieving long-term **growth and profitability** by strengthening our **nationwide core testing** business and expanding our **higher-growth, higher-value esoteric and genomic businesses**.

**LabCorp's Strategy**

11

**Strategic Focus Areas**

**Scientific**

**Leadership**

**Managed**

**Care**

**Customer**

**Retention**

-Licensing/partnerships

-Cancer

-Specimen tracking

-Call center consolidation

-Report improvement

-Acquisitions

-Appropriate prices

-Reduce leakage

-Value of new lab tests

-Customer connectivity

12

**Second Quarter Results (in millions, except per share data)**

6/30/04

6/30/05

+ / (-)

Revenue

\$784.3

\$853.3

8.8%

EBITDA

(1)

\$210.8

\$225.2

6.8%

EBITDA Margin

26.9%

26.4%

(50

bp)

Diluted EPS

(2)

\$0.66

\$0.76

15.2%

13

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 2nd quarter 2005 earnings release furnished on Form 8-K on July 21, 2005.

(2) Excluding \$0.02 per diluted share impact of a non-recurring investment loss.

**Six-Month Results (in millions, except per share data)**

6/30/04

6/30/05

+ / (-)

Revenue

\$1,536.8

\$1,652.4

7.5%

EBITDA

(1)

\$401.9

\$432.6

7.6%

EBITDA Margin

26.2%

26.2%

-

Diluted EPS

(2)

\$1.24

\$1.43

15.3%

14

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 2nd quarter 2005 earnings release furnished on Form 8-K on July 21, 2005.

(2) Excluding a \$0.02 per diluted share impact of a non-recurring investment loss.





**2005 Six-Month Financial  
Achievements**

Diluted EPS of \$1.43 (1)

EBITDA margin of 26.2% of sales

Operating cash flow of \$240.9 million

Increased revenues 7.5% (0.7% volume; 6.8%  
price)

Repurchased approximately \$122 million of  
LabCorp stock

Completed US LABS and Esoterix acquisitions

(1) Excluding a \$0.02 per diluted share impact of a non-recurring investment loss.

15

**Financial Performance**

*Price & Volumes: Trends by Payor Type*

**Client (Physicians)**

**Patient**

**Third Party**

**(MC/MD/Insurance)**

**Managed Care**

**Capitated**

**Fee for service**

**Total**

**LabCorp Total**

**2003**

**PPA**

**\$**

**Accessions**

**millions**

**\$27.07**

**118.48**

**34.25**

**9.95**

**45.68**

**32.74**

**\$33.43**

**31.7**

**2.5**

**18.1**

**12.9**

**22.7**

**35.6**

**87.9**

**2004**

**PPA**

**\$**

**millions**

**\$26.61**

**123.59**

**34.84**

**10.36**

**46.01**

**33.67**

**\$33.86**

**32.7**

**2.5**

**18.9**

**12.8**

**24.2**

**37.0**

**91.1**

**Accessions**

**YTD 2005**

**PPA**

**\$**

**millions**

**\$29.18**

**129.80**

**37.98**

**10.31**

**46.94**

**34.30**

**\$35.75**

**15.9**

**1.2**

**9.8**

**6.7**

**12.6**

**19.3**

**46.2**

**Accessions**

**16**

*Financial Performance*

**Revenue Analysis by Business Area**

**YTD JUN 2004**

**Revenue**

*% Accns*

**Accns**

**PPA**

**\$Million**

**to total**

**000**

**\$**

**Genomic**

**Identity/Gene  
Probes**

**All Genomic**

**Other Esoteric**

**Histology**

**All Genomic/  
Esoteric**

**Core**

**Total**

**\$143.1**

**1,228.2**

**2.7%**

**\$116.47**

**82.5**

**225.6**

**144.3**

**102.6**

**472.5**

**1,064.3**

**\$1,536.8**

**1,884.2**

**3,112.4**

**3,497.5**

**1,128.4**

**7,738.3**

**38,155.0**

**45,893.3**

**4.1%**

**6.8%**

**7.6%**

**2.5%**

**16.9%**

**83.1%**

**100.0%**

**43.80**

**72.48**

**41.26**

**90.92**

**61.06**

**27.90**

**\$33.49**

**YTD JUN 2005**

**Revenue**

*% Accns*

**Accns**

**\$Million**

**to total**

**000**

**\$164.4**

**1,401.1**

**3.1%**

**\$117.32**

**87.7**

**252.1**

**159.4**

**134.5**

**546.0**

**1,106.4**

**\$1,652.4**

**1,949.3**

**3,350.4**

**3,891.6**

**1,195.2**

**8,437.2**

**37,781.4**

**46,218.6**

**4.2%**



**7.3%**

**8.4%**

**2.6%**

**18.3%**

**81.7%**

**100.0%**

**44.98**

**75.23**

**40.97**

**112.53**

**64.71**

**29.28**

**\$35.75**

**PPA**

**\$**

**0.7%**

**2.7%**

**3.8%**

**(0.7%)**

**23.8%**

**6.0%**

**5.0%**

**6.8%**

**05 vs 04**

**PPA**

**Incr/(Decr)**



**Free Cash Flow Investment  
Strategy**

Acquisitions

Repayment of revolving line of credit

Stock repurchase program

Retain flexibility in utilizing remaining cash

18

**Updated 2005 Financial Guidance**

Revenue growth of approximately 8.5% to 9% compared to 2004, including in-year revenues of \$25 to \$35 million from small acquisitions and/or new contracts

EBITDA margins of 25.5% of revenues

Diluted EPS in the range of \$2.75 to \$2.80, including the \$0.02 impact of a non-recurring investment loss.

Capital expenditures of between \$110 and \$125 million

Free cash flow of between \$440 and \$465 million

19

**Financial Guidance for 2005**  
**(cont d.)**

Net interest expense of approximately \$32 million

Bad debt rate of approximately 5.3% of sales for the remainder of the year

Guidance does not include:

Possible significant contributions from new tests, or

The impact of new accounting for stock based compensation, or

Any potential restructuring charges as a result of the US LABS and Esoterix acquisitions.

20

*Other Financial Information*

*June 30, 2005*

**Depreciation**

**Amortization**

**Capital expenditures**

**Bad debt as a percentage of sales**

**Q1**

**Q2**

**23.2**

**Zero coupon-subordinated notes**

**Revolving credit facility  
(weighted average)**

**Cash flows from operations**

**Effective interest rate on debt:**

**5 1/2% Senior Notes (including  
effect of interest rate swap)**

**Days sales outstanding**

**YTD  
2005**

**\$**

**24.1**

**\$**

**47.3**

**\$**

**12.1**

**13.1**

**25.2**

25.5

20.2

45.7

154.4

86.5

240.9

5.5%

5.3%

5.4%

2.00%

2.00%

2.00%

5.38%

5.38%

5.38%

3.31%

3.62%

3.62%

55

55

55

\$

\$

\$

\$

\$

\$

\$

\$

\$

**(\$ in millions)**

21



